



# 21<sup>st</sup> ADVAC

## Advanced Course of Vaccinology

Les Pensières  
Center for Global Health  
Veyrier-du-Lac, France  
**11-22 May 2020**  
Application deadline:  
15 November 2019

Apply: [www.advac.org](http://www.advac.org)

For 20 years, ADVAC has provided senior decision-makers and scientists in the field of vaccines with a comprehensive overview of the latest advances, from immunology to vaccine development, including clinical trials. The social, economic, political and ethical issues of vaccination are also addressed during the lectures, which are given by a faculty of leading global experts.

## OVER 1,100 ADVAC ALUMNI WORLDWIDE

Through alumni get-together meetings and a variety of online resources (website), ADVAC continues to bring together vaccinologists throughout the world to discuss the major challenges of the day.

The relationships forged at ADVAC remain strong through meetings organized in parallel with international conferences/meetings such as those of the Scientific Advisory Group of Experts (SAGE), the European Society for Paediatric Infectious Diseases (ESPID), the Infectious Diseases Society of America (IDSA) and the Global NITAG Network (GNN). In the future collaboration will also take place in the context of Regional Immunization Programme Managers' meetings.

- 75 PARTICIPANTS**
- 70 INTERNATIONAL SPEAKERS**
- 13 INTERACTIVE SESSIONS**
- 11 DAYS OF KNOWLEDGE-SHARING**
- 20 SUCCESSFUL YEARS**
- 10 CASE STUDIES**
- 1 DIPLOMA AND CME CREDITS**
- A NETWORK OF OVER 1,100 ALUMNI**

For the 21<sup>st</sup> ADVAC, CME credits will be requested from the European Union of Medical Specialists - European Accreditation Council for Continuing Medical Education (UEMS-EACCME). CME credits can be converted by the American Medical Association (AMA) and other professional bodies.

### WHO SHOULD APPLY?

- Scientists and decision-makers involved in vaccine development, in the elaboration of new vaccination strategies or in policy decisions related to the introduction of new vaccines in public health programmes, at national or international levels.
- For both the public and private sectors.

Apply online through [www.advac.org](http://www.advac.org)  
Deadline: 15 November 2019 at 12:00 GMT.

### SELECTION CRITERIA

Participants (maximum 75) will be selected by the international Scientific Committee, according to their:

- Educational background,
- Involvement in vaccinology,
- Decision-making responsibility in vaccinology,
- Expected impact of the Course at personal, institutional and national levels (maximum one participant per institution).

### COURSE FEES

Accommodation fees (including all meals): €2,600

#### Registration fees

- Participants from academic/governmental institutions & NGOs benefit from reduced fees: €1,600 (VAT included)
- Participants from industry: SME and ADVAC sponsors from industry: €4,200
- Other industry participants: €9,200

The fees include tuition and course materials for the full period of the course.

If selected, participants will be required to pay all fees in full to confirm their participation.

#### Fellowships:

Fellowships covering travel expenses, registration and accommodation fees will be available for participants from low and middle income countries (with the support of the Bill & Melinda Gates Foundation). Other fellowships/scholarships will be provided by EDCTP, ESPID and NFID.

### VENUE

The course will be held at the Mérieux Foundation conference centre, Les Pensières Center for Global Health, Veyrier-du-Lac, on the scenic banks of Lake Annecy (France). Accommodation will be arranged in nearby hotels.

### CONTACT

[advac@unige.ch](mailto:advac@unige.ch)  
See additional info on:  
[www.advac.org](http://www.advac.org) • [www.fondation-merieux.org](http://www.fondation-merieux.org)



04-19 - Credit: photo: E. Bergand, A. Bouvier, F. Leclerc, S. Stock - thera - RSC Lyon B 396 160 242



Organized by

**The Mérieux Foundation  
and University of Geneva**

with the co-sponsorship of

- Bill & Melinda Gates Foundation
- Centers for Disease Control and Prevention (CDC)
- European Centre for Disease Prevention and Control (ECDC)
- European & Developing Countries Clinical Trials Partnership (EDCTP)
- European Society for Paediatric Infectious Diseases (ESPID)
- Johns Hopkins Bloomberg School of Public Health
- National Foundation for Infectious Diseases (NFID)
- National Institutes of Health (NIH/NIAID-USA) and Fogarty International Center
- World Health Organization



**UNIVERSITÉ  
DE GENÈVE**





**Neal Halsey,**  
Professor - Department  
of International Health,  
Bloomberg School of Public  
Health, Baltimore

“ ADVAC helps fulfill the prescient vision of Dr. Charles Mérieux to gather scientists and other health professionals to address the never-ending challenges from infectious diseases. Past ADVAC participants have helped bring new lifesaving vaccines to countries throughout the world and they are playing key roles in the development of new vaccines. ”

**Objective:** to facilitate critical decision-making in vaccinology by providing participants with a comprehensive overview of the field, from immunology to vaccine development, including clinical trials and the social, economic, political and ethical issues of vaccination.

## PROVISIONAL PROGRAMME

### SESSION 1 THE MULTI-FACETED NATURE OF VACCINOLOGY

- How to develop a new programme of immunization
- Access to vaccination in GAVI countries and, at global level
- Are vaccines always cost-effective?
- Industrial vision of vaccinology in industrialized and developing countries

### SESSION 2 HOW VACCINES WORK

- How are vaccine responses elicited?
- Immunological basis for responses to mucosal vaccines
- Immunological correlates of immunity
- Vaccines and immunological memory

### SESSION 3 DECISION-MAKING IN VACCINE R&D

- New approaches to vaccine development and delivery
- How do vaccines cause adverse events
- From pre-clinical research to vaccine development
- Vaccine adjuvants: pragmatic approaches

### SESSION 4 ASSESSING VACCINES IN CLINICAL TRIALS (I)

- Sequential stages of clinical trials and overview of issues to be considered
- How to design, recruit volunteers for, and analyze the results of selected phase II trials
- How to design a phase II trial

### SESSION 5 ASSESSING VACCINES IN CLINICAL TRIALS (II)

- Lessons from pitfalls experienced in the registration process
- Clinical trials: role of a Data and Safety Monitoring Board (DSMB)
- Designing and analyzing the results of 3 selected phase III trials

### SESSION 6 VACCINE SAFETY

- Lessons from previous adverse effects of vaccination and assessment of causal relationships
- Immunological safety of vaccination
- Population-based post-licensure surveillance
- Immunization safety in developing country vaccination programmes
- Vaccine hesitancy and risk communication: an overview

### SESSION 7 ETHICAL ISSUES

- Ethical issues related to clinical trials
- Group exercises

### SESSION 8 INTRODUCING NEW VACCINES INTO VACCINATION PROGRAMMES

- Disease burden and the public health value of vaccines
- Role of epidemiology and health economics
- Development of national vaccination recommendations and policies
- Approaches to help the decision-making process
- Adjusting vaccination strategies
- Biology of bacterial pathogens and its importance for vaccination
- Vaccination in the elderly
- Influenza biology and vaccination strategies for different age groups
- Rotavirus vaccines
- HPV vaccines
- Dengue vaccines
- New vaccines: Malaria, Tuberculosis, HIV, RSV
- Case specific studies: Meningococcal vaccines, Combination vaccines, Influenza-vaccination strategies, Pneumococcal conjugates, HPV, Rotavirus, Japanese Encephalitis, Dengue, Shingles

### SESSION 9 SELECTING APPROPRIATE VACCINATION STRATEGIES

- Vaccines for maternal-neonatal health
- Vaccination schedules
- Vaccination in immune-compromised individuals
- Impact of vaccination on disease epidemiology
- Outbreaks' control: Elimination and eradication strategies
- Increasing vaccination coverage
- Vaccination in humanitarian emergencies situations

### SESSION 10 FACING THE MEDIA

- Introduction to media dynamics: How to best deliver vaccinology-related messages to different interest groups



## SAMPLE OF REGULAR LECTURERS

**RAFI AHMED**  
Emory University, USA

**ROY ANDERSON**  
Imperial College London, UK

**NICK ANDREWS**  
Public Health England, UK

**EDWIN ASTURIAS**  
Children's Hospital Colorado, USA

**NORMAN BAYLOR**  
BCG, USA

**CRISTINA CASSETTI**  
NIAID, NIH, USA

**JOHN CLEMENS**  
icddr.b, Bangladesh

**RON DAGAN**  
Soroka Medical Center, Israel

**PHILIPPE DUCLOS**  
University of Geneva, Switzerland

**JANET ENGLUND**  
Seattle Children's Hospital, USA

**ADAM FINN**  
University of Bristol, UK

**MARTIN FRIEDE**  
WHO, Switzerland

**BERNARD FRITZELL**  
BFL Conseils, France

**ROGER GLASS**  
Fogarty International Center, NIH, USA

**DAVID GOLDBLATT**  
Institute of Child Health, University College London, UK

**DEBORAH HALL**  
Journalist, UK

**NEAL HALSEY**  
J.H. Bloomberg School of Public Health, USA

**PENNY HEATON**  
Bill & Melinda Gates Foundation  
Medical Research Institute, USA

**CAROLE HEILMAN**  
Formerly NIAID, NIH, USA

**KARI JOHANSEN**  
ECDC, Sweden

**PAUL-HENRI LAMBERT**  
University of Geneva, Switzerland

**MYRON LEVINE**  
University of Maryland, USA

**NONI MCDONALD**  
Dalhousie University, Canada

**MARK MILLER**  
NIH, USA

**PIETER NEELS**  
Vaccine-Advice, Belgium

**KATHY NEUZIL**  
CVD Baltimore, USA

## SCIENTIFIC COMMITTEE

**EDWIN ASTURIAS**  
Children's Hospital Colorado, USA

**ANANDA BANDYOPADHYAY**  
Bill & Melinda Gates Foundation

**JULIET BRYANT**  
Mérieux Foundation, France

**PHILIPPE DUCLOS**  
University of Geneva, Switzerland

**EMILY ERBELDING** NIAID, NIH, USA

**ADAM FINN** University of Bristol, UK

**MARTIN FRIEDE** WHO, Switzerland

**ROGER GLASS**  
Fogarty International Center, NIH, USA

**NEAL HALSEY**  
J.H. Bloomberg School of Public Health, USA

**CAROLE HEILMAN**  
Formerly NIAID, NIH, USA

**KARI JOHANSEN** ECDC, Sweden

**PAUL-HENRI LAMBERT**  
University of Geneva, Switzerland

**MICHAEL MAKANGA**  
EDCTP, the Netherlands

**MARK MILLER** NIH, USA

**HANNA NOHYNEK**  
National Institute for Health and Welfare, Finland

**STANLEY PLOTKIN**  
University of Pennsylvania, USA

**CLAIRE-ANNE SIEGRIST**  
University of Geneva, Switzerland

**KEIPP TALBOT** NFI, USA

**HANNA NOHYNEK**  
National Institute for Health and Welfare, Finland

**UMESH PARASHAR**  
CDC, USA

**ANDREW POLLARD**  
Oxford University, UK

**STANLEY PLOTKIN**  
University of Pennsylvania, USA

**DAVID SALISBURY**  
Centre on Global Health Security, UK

**CLAIRE-ANNE SIEGRIST**  
University of Geneva, Switzerland

**CATHERINE SLACK**  
University of KwaZulu-Natal, South Africa

**PETER SMITH**  
London School of Hygiene & Tropical Medicine, UK